The Latest Breaking News from Assembly Bio

Gilead (GILD) Quarterly Earnings: Buy or Sell Signal?

Biotech major Gilead Sciences (GILD) will release its fourth-quarter results on February 6. The company is expected to report growth in earnings over the prior-year quarter, but its revenue is expected to decline. Given the expected decline in its revenue, how should investors play this stock? Read on to learn…

StockNews.com · Feb 5, 2024

The Daily Biotech Pulse: Third FDA Rejection For Verrica's Skin Disease Drug, Assembly Bio Terminates Hepatitis B Virus Pact, Consistency Data For Valneva's Chikungunya Vaccine

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga · May 25, 2022